Entrada Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Entrada Therapeutics has a total shareholder equity of $422.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $554.6M and $132.1M respectively. Entrada Therapeutics's EBIT is $57.8M making its interest coverage ratio -3.1. It has cash and short-term investments of $449.3M.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | -3.1x |
| Cash | US$449.34m |
| Equity | US$422.45m |
| Total liabilities | US$132.14m |
| Total assets | US$554.59m |
Recent financial health updates
Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?
Mar 08
We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
Sep 11We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
May 28We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth
Jan 31Recent updates
There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding
Oct 17Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher
Aug 23Entrada Therapeutics: A Complicated Tale
Jun 16Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry
May 29These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts
Mar 19This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year
Nov 09Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)
May 26Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts
May 14Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?
Mar 08We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
Sep 11Entrada Therapeutics GAAP EPS of -$0.74 misses by $0.02
Aug 11We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
May 28We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth
Jan 31Financial Position Analysis
Short Term Liabilities: TRDA's short term assets ($465.3M) exceed its short term liabilities ($70.6M).
Long Term Liabilities: TRDA's short term assets ($465.3M) exceed its long term liabilities ($61.5M).
Debt to Equity History and Analysis
Debt Level: TRDA is debt free.
Reducing Debt: TRDA has not had any debt for past 5 years.
Debt Coverage: TRDA has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: TRDA has no debt, therefore coverage of interest payments is not a concern.